Progressive supranuclear palsy: In vivo SPECT imaging of presynaptic vesicular acetylcholine transporter with [123I]-iodobenzovesamicol

Radiology

Volumn 265, Issue 2, 2012, Pages 537-543

  Mazer̀e, Joachim ^a,b   Meissner, Wassilios G ^b,c   Mayo, Willy ^a   Sibon, Igor ^a,b   Lamare, Fred́éric ^a,b   Guilloteau, Denis ^d   Tison, Franco̧is ^b,c   Allard, Michel̀e ^a,b,e  

^a UMR 5287   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d UNIVERSITÉ DE TOURS   (France)

^e PSL RESEARCH UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IODOBENZOVESAMICOL I 123; TRACER; UNCLASSIFIED DRUG; VESICULAR ACETYLCHOLINE TRANSPORTER;

ADULT; ANTERIOR CINGULATE; ARTICLE; BINDING POTENTIAL VALUE; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE DURATION; FEMALE; HIPPOCAMPUS; HUMAN; IN VIVO STUDY; INNOMINATOCORTICAL CHOLINERGIC PATHWAY; MALE; NERVE TRACT; NUCLEAR MAGNETIC RESONANCE IMAGING; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; PONTOTHALAMIC CHOLINERGIC PATHWAY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROSPECTIVE STUDY; PROTEIN BINDING; PROTEIN EXPRESSION; SEPTOHIPPOCAMPAL CHOLINERGIC PATHWAY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THALAMUS;

AGED; BRAIN; FEMALE; HUMANS; MALE; PIPERIDINES; PRESYNAPTIC TERMINALS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUPRANUCLEAR PALSY, PROGRESSIVE; TETRAHYDRONAPHTHALENES; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VESICULAR ACETYLCHOLINE TRANSPORT PROTEINS;

EID: 84867912733     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12112650     Document Type: Article

References (26)

1. Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009;8(3):270-279.
2. Ruberg M, Javoy-Agid F, Hirsch E, et al. Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol 1985;18(5):523-529. (Pubitemid 16258085)
3. Kish SJ, Chang LJ, Mirchandani L, Shannak K, Hornykiewicz O. Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers. Ann Neurol 1985;18(5):530-536. (Pubitemid 16258086)
4. Suzuki M, Desmond TJ, Albin RL, Frey KA. Cholinergic vesicular transporters in progressive supranuclear palsy. Neurology 2002;58(7):1013-1018. (Pubitemid 34298538)
5. Gilman S, Koeppe RA, Nan B, et al. Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes. Neurology 2010;74(18):1416-1423.
6. Asahina M, Suhara T, Shinotoh H, Inoue O, Suzuki K, Hattori T. Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study. J Neurol Neurosurg Psychiatry 1998;65(2):155-163. (Pubitemid 28371923)
7. Kuhl DE, Koeppe RA, Fessler JA, et al. In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM. J Nucl Med 1994;35(3):405-410. (Pubitemid 24079964)
8. Wevers A. Localisation of pre- and post-synaptic cholinergic markers in the human brain. Behav Brain Res 2011;221(2):341-355.
9. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47(1):1-9. (Pubitemid 26243849)
10. Mazère J, Prunier C, Barret O, et al. In vivo SPECT imaging of vesicular acetylcholine transporter using [(123)I]-IBVM in early Alzheimer's disease. Neuroimage 2008;40(1):280-288.
11. Giovacchini G, Lerner A, Toczek MT, et al. Brain incorporation of 11C-arachidonic acid, blood volume, and blood flow in healthy aging: a study with partial-volume correction. J Nucl Med 2004;45(9):1471-1479. (Pubitemid 47618500)
12. Meltzer CC, Kinahan PE, Greer PJ, et al. Comparative evaluation of MR-based partial-volume correction schemes for PET. J Nucl Med 1999;40(12):2053-2065. (Pubitemid 30022022)
13. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15(1):273-289. (Pubitemid 34852226)
14. Barret O, Mazère J, Seibyl J, Allard M. Comparison of noninvasive quantification methods of in vivo vesicular acetylcholine transporter using [123I]-IBVM SPECT imaging. J Cereb Blood Flow Metab 2008;28(9):1624-1634.
15. McGeer PLES, McGeer EG. Molecular neurobiology of the mammalian brain. New York, NY: Plenum, 1980.
16. Araujo DM, Lapchak PA, Robitaille Y, Gauthier S, Quirion R. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. J Neurochem 1988;50(6):1914-1923.
17. Erickson JD, Varoqui H, Schäfer MK, et al. Functional identification of a vesicular acetylcholine transporter and its expression from a "cholinergic" gene locus. J Biol Chem 1994;269(35):21929-21932.
18. Kuhl DE, Minoshima S, Fessler JA, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 1996;40(3):399-410. (Pubitemid 26304797)
19. Bohnen NI, Frey KA. Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders. Mol Imaging Biol 2007;9(4):243-257. (Pubitemid 47028740)
20. Bird TD, Stranahan S, Sumi SM, Raskind M. Alzheimer's disease: choline acetyltransferase activity in brain tissue from clinical and pathological subgroups. Ann Neurol 1983;14(3):284-293. (Pubitemid 13051231)
21. Perry RH, Candy JM, Perry EK, Thompson J, Oakley AE. The substantia innominata and adjacent regions in the human brain: histochemical and biochemical observations. J Anat 1984;138(Pt 4):713-732. (Pubitemid 14120134)
22. Gilman S, Koeppe RA, Chervin RD, et al. REM sleep behavior disorder is related to striatal monoaminergic deficit in MSA. Neurology 2003;61(1):29-34. (Pubitemid 36818742)
23. Shinotoh H, Namba H, Yamaguchi M, et al. Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy. Ann Neurol 1999;46(1):62-69. (Pubitemid 29314383)
24. Hirano S, Shinotoh H, Shimada H, et al. Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia. Brain 2010;133(Pt 7):2058-2068.
25. Jenkinson N, Nandi D, Muthusamy K, et al. Anatomy, physiology, and pathophysiology of the pedunculopontine nucleus. Mov Disord 2009;24(3):319-328.
26. Tagliavini F, Pilleri G, Bouras C, Constantinidis J. The basal nucleus of Meynert in patients with progressive supranuclear palsy. Neurosci Lett 1984;44(1):37-42. (Pubitemid 14161741)